COVAXIN, is one of the three approved vaccines against COVID-19 being administered in India, developed by Indian Council of Medical Research (ICMR) and Bharat Biotech.
The Hyderabad-based Bharat Biotech has finally submitted the Phase-III trial data of COVAXIN, a move highly awaited by most Indians. While it has been administered to crores of people, a large section of the population is apprehensive against COVAXIN. The new trial data will reduce vaccine hesistancy among the masses.
The data was submitted to DCGI (Drugs Controller General of India) over the weekend. This will also speed up the process to get WHO approval.
A Subject Expert Committee is likely to meet on Tuesday, 22nd June, to review the Phase-III study data submitted by Bharat Biotech. The other two vaccines being administered in India are Covishield (license-produced AstraZeneca-Oxford AZD1222 vaccine) and Russian Sputnik V. The interim data revealed by Bharat Biotech claimed that COVAXIN was 78% effective against symptomatic disease and 100% against serious illness.
The full vaccination for COVAXIN is achieved with two doses given with a 4-week gap.